UroGen Pharma (NASDAQ:URGN) has added two of its senior employees to the C-suite. The Princeton, NJ-based company, which Wednesday received FDA approval of its lead drug, promoted its senior vice president of commercial, Jeff Bova, to chief commercial officer, and its senior vice president of clinical development, Elyse Seltzer, to chief development officer. Bova and […]

Some of the targets in cancer research are visible and well known, but they’re hard to hit with new drugs all the same. PIC Therapeutics is developing medicines aiming for one particularly elusive group of proteins, and the startup’s early research has attracted financial support from some prominent names in the life sciences industry. PIC […]

Limited data isn’t an issue when it comes to how to best use computational tools to better prevent disease and treat patients—but how to more efficiently analyze existing information is. Industry veterans with experience in life sciences and data science floated their ideas about how the pharmaceutical industry could better plug in to the “big […]

An AstraZeneca drug designed to block tumor growth is now approved as a treatment for neurofibromatosis type 1 (NF1), a rare inherited disorder that leads to tumors on nerves throughout the body. The FDA’s Friday decision for the drug, selumetinib (Koselugo), makes it the first approved treatment for NF1. It’s also the latest twist in […]

Aravive (NASDAQ: ARAV) on Thursday said Gail McIntyre, the company’s chief scientific officer, has been promoted to CEO. McIntyre, who joined the company since 2016, succeeds Rekha Hemrajani, who has resigned, along with three board directors. The company called the leadership transition a “natural evolution” following its company’s reverse merger in June 2018 with Versartis, […]

Talking to a healthcare provider from the safety of one’s own home make more sense than ever today. Tyto Care offers a way to do so, plus a device that allows consumers to perform exams and transmit video, images, and sounds to their provider. This week the telehealth company doubled its outside investment to fuel […]

The financial markets may remain volatile but Keros Therapeutics (NASDAQ: KROS) managed to raise more money in its public market debut than it had initially planned. Late Tuesday the Lexington, MA-based company offered 6 million shares for $16 apiece, the high end of its projected price range. Keros had previously planned to offer 5 million […]

Millendo Therapeutics is considering a corporate reorganization after its lead drug, an investigational treatment for a rare genetic condition characterized by unrelenting hunger, did not perform better than a placebo in a pivotal trial. The Ann Arbor, MI-based company said Monday that the drug, livoletide, did not meet the goal of the Phase 2b study […]

Last month French biotech Dynacure dosed the first patient in an early-stage trial of its lead drug candidate, a treatment for a group of rare genetic muscle disorders. Now the company, which also has an office in Philadelphia, has landed a €50 million ($55 million) Series C financing round to move that investigational antisense medicine, […]

Locana has appointed Micah Mackison as its chief business officer to lead business development and corporate communications. Mackison most recently led business development efforts at Assembly Biosciences (NASDAQ: ASMB) as senior vice president, corporate development and strategy. Previously he led healthcare transactions at Jabil as senior director, corporate investment, and served as head of corporate […]

Immunotherapies called checkpoint inhibitors have helped change the way a number of cancers are treated by blocking a tumor cell’s ability to hide from the immune system. Some patients don’t respond, however, or develop resistance to these drugs. Iteos Therapeutics has raised $125 million to advance new cancer treatments it is developing to target two […]